After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

Formulated, Science-Backed Supplements Trusted by Thousands-And See Why Advanced BioNutritionals Sets the Gold Standard in ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...

A novel drug for bloodstream infections, code-named VRP-034 and currently in the development stage pending final trials and ...

Significant proposed regulatory changes within the U.S. Food and Drug Administration (FDA), along with large layoffs that ...